|
Emicizumab as prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages), Policy Position Statement (PP167). November 2018 (PDF, 316Kb)
|
|
Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189). August 2019 (PDF, 311Kb)
|
|
Inherited Bleeding Disorders, Service Specification (CP77). May 2014 (PDF, 263Kb)
|
|
Sickle Cell Disorders, Thalassaemia Disorders and other Rare Hereditary Anaemias, Service Specification (CP179). December 20201.0 (PDF, 530Kb)
|
|
Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease, Policy Position Statement (PP215), May 2021 (PDF, 329Kb)
|